As July comes to a close, we are three weeks out from the Cambridge Healthtech Institute Bioprocessing Summit. Our team will be onsite in booth TT5 to chat #genetherapy. Will we see you there?
Ascend Advanced Therapies
Biotechnology Research
Ascend is a gene therapy development partner with a flexible platform featuring industry-leading analytics.
About us
Ascend is an end-to-end gene therapy development partner with deep expertise in gene therapy development and commercialization. We offer unparalleled collaboration while working to develop your products from the bench through the clinic and beyond. Scientific innovation driven by quality and responsibility are at the core of our business. To set a new standard in the industry, we have invested in a world-class analytical toolkit within our flexible and scalable AAV platform of next-gen technologies, all built to find the perfect balance of yield and quality for each process. Let’s aim higher and develop the next wave of accessible life-saving therapies together!
- Website
-
https://www.ascend-adv.com/
External link for Ascend Advanced Therapies
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
London, GB
-
Munich, DE
-
San Francisco, US
-
14193 NW 119th Terrace
Alachua, Florida 32615, US
Employees at Ascend Advanced Therapies
Updates
-
Last month, we had the pleasure of hosting a small group of #genetherapy experts to discuss #industry trends and challenges. Markus Hörer and Sonya Schermann presented how our modular AAV platform and unmatched analytical portfolio are curated to overcome these challenges by balancing high quality, yield and potency from gene to GMP. Thank you to the attendees for making time to provide input on the evolution of our platform here at Ascend.
-
Demand for high quality AAV vectors continues to grow, as the number of #genetherapy trials and approvals increases. Let's do a #TBT to the American Society of Gene & Cell Therapy, where our team presented 11 posters at the event! Poster 561 showed how our EpyQ system combines with our suspension HEK293 cell line to create a robust and scalable platform for high quality AAV vector manufacturing.
-
The ESACT - European Society for Animal Cell Technology Congress 2024 in Edinburgh did not disappoint! Here's a few photos from our time onsite, which was filled with posters, presentations, intriguing discussions and laughs. It's such a pivotal time in #cellandgenetherapy, and we feel honored to play a part in keeping #genetherapy progress moving ahead.
-
In a recent chat with our CSO, Markus Hörer, we outlined the importance of AAV process comparability throughout #genetherapy #development. Building processes that are comparable across all scales from R&D through commercial manufacturing from the start simplifies #commercialization. Read the full blog here: https://lnkd.in/eA4KCE9e
-
What a week with our team in Edinburgh at the ESACT - European Society for Animal Cell Technology Congress digging in to the latest progress in #genetherapy. Stay tuned because we'll take a look back on our adventures there next week. But just in case you missed us onsite or did not make the event at all, we thought we'd share a little about who we are! https://lnkd.in/gWE6ebFe Reach out to chat #innovation any time here or via business@ascend-adv.com.
-
Have you been wondering how to optimize your rAAV production? And you're at ESACT - European Society for Animal Cell Technology? Check out poster 291 from Johanna Wagner, PhD to learn more. You may even meet the hype team (and our Sunday presenters, Ahmed Youssef and Markus Hörer), too!
-
Did you start your week in #Edinburgh at the ESACT - European Society for Animal Cell Technology Congress? A handful of our team started with #genetherapy presentations yesterday. And for the duration of the event, check out Johanna Wagner, PhD presenting poster 291 on the impact of the N-1 seed train on rAAV production #efficiency. Missed a presentation or poster, or maybe the whole event? That's okay! We are available at business@ascend-adv.com any time.
-
Happy Friday! The ESACT - European Society for Animal Cell Technology Congress is just around the corner now. Come see our CSO, Markus Hörer discussing "Transitioning Advanced Therapies from Research to Development and #Manufacturing - What Have We Learned About Developability?" with Boehringer Ingelheim on Sunday, June 23 at 1:00. Can't make it to the talk? No worries! We're always accessible to chat #genetherapy via DM or business@ascend-adv.com.
-
The clock is ticking towards the ESACT - European Society for Animal Cell Technology Congress starting this Sunday, June 23 in #Edinburgh, Scotland! Ahmed Youssef will be onsite helping to invigorate day one with a talk about #genetherapy #commercialization hosted by Sartorius at 1:30pm. Looking to connect, or can't make it to the talk and want the highlights? We are always accessible at business@ascend-adv.com or by DM to follow up.